TP53 and neoplasm: Indeed, continuous treatment with Rapamycin or a novel Rapamycin formulation (Rapatar) delayed carcinogenesis in tumor-prone p53+/−and p53−/−mice respectively, most likely by slowing down the process of aging [37, 38].